Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAM-760 added to donepezil in mild to moderate Alzheimer's disease with neuropsychiatric symptoms
2014-000830-42Phase 2Terminated
- Sponsor
- Pfizer
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing SAM-760 + donepezil with Placebo + donepezil (2 arms). Primary endpoint: Change from baseline in ADAS-cog13 total score at 12 weeks after start of double-blind treatment. Started May 2014; status: terminated.
02
Drugs
PF-05212377
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2014-000830-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000830-42.